Literature DB >> 8824277

Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter.

E T Keller1, C Chang, W B Ershler.   

Abstract

Androgens repress expression of many genes, yet the mechanism of this activity has remained elusive. The cytokine, interleukin-6, is active in a variety of biological systems, and its expression is repressed by androgens. Accordingly we dissected the mechanism of androgen's ability to inhibit interleukin-6 expression at the molecular level. In a series of co-transfection assays, we found that 5alpha-dihydrotestosterone, through the androgen receptor, repressed activation of the interleukin-6 promoter, in part, by inhibiting NFkappaB activity. It did not appear that 5alpha-dihydrotestosterone inhibited NFkappaB by activating the androgen receptor to compete for the NFkappaB response element as we could not detect androgen receptor binding to the IL-6 promoter by DNase I footprinting assay. However, by electrophoretic mobility shift assay we found that 5alpha-dihydrotestosterone repressed formation of NFkappaB middle dotNFkappaB response element complex formation. In LNCaP prostate carcinoma cells, 5alpha-dihydrotestosterone achieved this effect through maintenance of IkappaBalpha protein levels in the face of phorbol ester, a stimulus that results in IkappaBalpha degradation. Finally, we confirmed that IkappaBalpha inhibits NFkappaB-mediated activation of the interleukin-6 promoter. These data suggest that maintenance of IkappaBalpha levels may represent the first identified mechanism for androgen-mediated repression of a natural androgen-regulated gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824277     DOI: 10.1074/jbc.271.42.26267

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Differential regulation of testosterone vs. 5alpha-dihydrotestosterone by selective androgen response elements.

Authors:  P W Hsiao; T H Thin; D L Lin; C Chang
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 2.  Frailty and hormones.

Authors:  John E Morley; Moon Jong Kim; Matthew T Haren
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 3.  Interleukin-6 in aging and chronic disease: a magnificent pathway.

Authors:  Marcello Maggio; Jack M Guralnik; Dan L Longo; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-06       Impact factor: 6.053

4.  Anemia in frailty.

Authors:  Cindy N Roy
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

Review 5.  Unexplained anemia in the elderly.

Authors:  Sasan Makipour; Bindu Kanapuru; William B Ershler
Journal:  Semin Hematol       Date:  2008-10       Impact factor: 3.851

Review 6.  Relations between steroid hormones and cytokines in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  M Cutolo; A Sulli; B Villaggio; B Seriolo; S Accardo
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

Review 7.  Cytokine and endocrine signaling in prostate cancer.

Authors:  J Puente Vazquez; E Grande Pulido; L M Anton Aparicio
Journal:  Med Oncol       Date:  2011-08-20       Impact factor: 3.064

8.  The IκB Kinases Restrict Human Cytomegalovirus Infection.

Authors:  Christopher M Goodwin; Joshua Munger
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

9.  Activation of hepatitis B virus S promoter by a cell type-restricted IRE1-dependent pathway induced by endoplasmic reticulum stress.

Authors:  Zhi-Ming Huang; Thomas Tan; Hiderou Yoshida; Kazutoshi Mori; Yanjun Ma; T S Benedict Yen
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  Signal transduction inhibition of APCs diminishes th17 and Th1 responses in experimental autoimmune encephalomyelitis.

Authors:  Mario Skarica; Tianhong Wang; Erin McCadden; David Kardian; Peter A Calabresi; Donald Small; Katharine A Whartenby
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.